AI assistant
ABBOTT LABORATORIES — Director's Dealing 2024
Feb 23, 2024
29777_dirs_2024-02-23_2ca188e3-bbf2-4d73-bc65-40ca1029de3c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2024-02-21
Reporting Person: Earnhardt Lisa D (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-21 | Common shares without par value | A | 17240 | — | Acquired | 92677 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-21 | Option (right to buy) | $116.98 | A | 64787 | Acquired | 2034-02-20 | Common Shares (64787) | Direct |
Footnotes
F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,595 on February 21, 2025, 21,596 on February 21, 2026, and 21,596 on February 21, 2027.